Please assess the completion status of the following clinical trial:

Trial Title: Lucentis in Advanced Macular Degeneration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subjects will be eligible if the following criteria are met:~* Ability to provide written informed consent and comply with study assessments for the full duration of the study.~* Age \> 50 years.~* Low vision AMD patients with a VA of 20/400 or worse.~* Evidence of active exudation as manifested by subretinal or intraretinal fluid on OCT or fresh appearing subretinal hemorrhage on fundus examination.~Exclusion Criteria:~Subjects who meet any of the following criteria will be excluded from this study:~* Pregnancy (positive pregnancy test) or lactation.~* Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch.~* Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated.~* Participation in another simultaneous medical investigation or trial.~* Concurrent eye disease in the study eye that could compromise visual acuity (e.g., diabetic retinopathy, advanced glaucoma).

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ranibizumab Group 1 (Type: OTHER): Group 1: 3 monthly injections of 0.5mg then prn
- ranibizumab Group 2 (Type: OTHER): Group 2: 6 monthly injections of 0.5 mg then prn

Based on this trial design, predict the completion outcome and termination type (if applicable).